Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136.1 CHF | +6.20% |
|
-.--% | -.--% |
07-02 | Evercore ISI Adjusts Price Target on Zimmer Biomet Holdings to $115 From $130, Maintains In-Line Rating | MT |
07-01 | Zimmer Biomet Shares Fall Following Piper Sandler Downgrade | MT |
Evolution of the average Target Price on Zimmer Biomet Holdings, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Zimmer Biomet Holdings, Inc.
Barclays | |
Argus | |
Raymond James | |
UBS | |
Truist Securities | |
Bernstein | |
Jefferies & Co. | |
Citigroup | |
Morgan Stanley | |
Oppenheimer | |
BTIG | |
Deutsche Bank Securities | |
RBC Capital Markets | |
Evercore ISI | |
JMP Securities | |
Stifel Nicolaus | |
JPMorgan Chase | |
Baird | |
BofA Securities | |
Piper Sandler | |
Wells Fargo Securities | |
Goldman Sachs | |
Needham & Co. | |
SVB Leerink | |
Guggenheim | |
Loop Capital | |
Canaccord Genuity | |
Ned Davis Research | |
J.P. Morgan Chase | |
Northland Securities |
EPS Revisions
- Stock Market
- Equities
- ZBH Stock
- 0QQD Stock
- Consensus Zimmer Biomet Holdings, Inc.